Interim FDG-PET Scan in Hodgkin's Lymphoma:  Hopes and Caveats by André, M. et al.
Hindawi Publishing Corporation
Advances in Hematology
Volume 2011, Article ID 430679, 6 pages
doi:10.1155/2011/430679
Review Article
InterimFDG-PET Scan in Hodgkin’s Lymphoma:
Hopes and Caveats
M. Andr´ e,1 T. Vander Borght,2 and A. Bosly3
1Department of Hematology, Grand Hˆ opital de Charleroi, Grand Rue, 3, 6000 Charleroi, Belgium
2Department of Nuclear Medecine, Universit´ e Catholique de Louvain, Cliniques Universitaires UCL de Mont Godinne, Yvoir, Belgium
3Department of Hematology, Universit´ e Catholique de Louvain, Cliniques Universitaires UCL de Mont Godinne, Yvoir, Belgium
Correspondence should be addressed to M. Andr´ e, marc.andre@docs.be
Received 29 June 2010; Accepted 1 November 2010
Academic Editor: Emanuele Zucca
Copyright © 2011 M. Andr´ e et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
FDG-PET has recently emerged as an important tool for the management of Hodgkins lymphoma. Although its use for initial
staging and response evaluation at the end of treatment is well established, the place of interim PET for response assessment
and subsequent treatment tailoring is still quite controversial. The use of interim PET after a few cycles of chemotherapy may
allow treatment reduction for good responders, leading to lesser treatment toxicities as well as early treatment adaptation for
bad responders with a potential higher chance for cure. Interpretation of interim PET is a rapidly moving ﬁeld. Actually, visual
interpretation is preferred over quantitative interpretation in this situation. The notion of minimal residual uptake emerged for
faint persisting FDG uptake, but has evolved during the recent years. Guidelines using mediastinum and liver as references have
been proposed at the expert meeting in Deauville 2009. Actually, several trials are ongoing both for localised and advanced disease
to evaluate the FDG-PET potential for early treatment monitoring and tailoring. Until the results of these prospective randomized
trials become available, treatment changes according to the interim PET results should remain inappropriate and limited to well-
conducted clinical trials.
1.Introduction
This paper presents the latest evidence for the use and inter-
pretation of early interim 18F-ﬂuorodeoxyglucose positron
emission tomography (PET) in classical Hodgkin’s lym-
phoma (cHL).
The treatment of cHL is classically based on Ann Arbor
staging.
Patients with limited disease (stage I-II) receive combi-
ned modality treatment mostly consisting of a few cycles
of adriamycin, bleomycin, vinblastine and dacarbazine
(ABVD), followed by involved-ﬁeld radiotherapy 20–30Gy
[1]. This approach leads to very high event-free and overall
survival (10-year overall survival estimates ranging from
84 to 97%). However, these young patients experience late
toxicities, such as secondary tumours and cardiac events,
mostly related to radiotherapy, which lead to a delayed mor-
tality [2]. Diﬀerent randomised trials attempted to withdraw
radiotherapy for unselected limited-disease patients. All of
them showed reduced event-free survival for non irradiated
patients [3–5]. Two recent GHSG (German Hodgkin Study
Group) trials demonstrated that it is, nevertheless, possible
to reduce the dose from 30 to 20Gy in unselected patients
with favourable disease [6, 7]. A concomitant expected
decrease in late toxicities has not been observed yet, and our
ﬁnal goal remains to avoid radiotherapy for selected cHL
patients.
Patients with advanced disease (bulky stage II with B
symptoms and stages III-IV) receive generally 6–8 cycles of
chemotherapy, mainly ABVD or BEACOPPesc. Their 10-
year overall survival range from 75% to 85% [8]. If there
a r es o m ee v i d e n c et h a tB E A C O P P e s ci sm o r ee ﬀective than
ABVD [9], this regimen also shows increased immediate
(haematological)anddelayed(fertility,myelodysplasia,acute
myeloid leukemia) toxicities. It would be therefore, of major
interest to be able to distinguish patients who can be
cured with only a few cycles of BEACOPPesc or ABVD
from patients who need a full course of 6–8 cycles of
BEACOPPesc or even more aggressive treatments with high-
dose chemotherapy and stem cell transplantation upfront.2 Advances in Hematology
Overthelastdecade,FDG-PEThasbecomeanimportant
component in staging and end of treatment response assess-
ment of patients with cHL [10]. When PET is combined
with a CT scan (PET/CT), PET readings improve, actually
PET/CT is the standard [11]. The adjunct of IV contrast-
enhanced CT is likely to enhance the beneﬁt even further
[12], but this is debated as other authors report that in
patients undergoing PET/CT for staging or restaging after
therapy of lymphoma, diagnostic CT with IV contrast does
not add useful information regarding extent of lymphoma if
the low-dose CT scan is interpreted individually [13]. The
spread of PET/CT is rapidly expanding, and its use should
be carefully evaluated. Its role to evaluate residual masses at
the end of treatment is ﬁrmly established and has become a
standard of care. For staging, FDG-PET leads 15%–20% and
5%–15% changes in stage and treatment, respectively [14].
The impact of these treatment modiﬁcations has, however,
never been evaluated prospectively. The use of FDG-PET
for radiotherapy planning in Stage I or II cHL may induce
signiﬁcant irradiated ﬁeld modiﬁcations, but today there are
no validated guidelines to integrate such information in the
treatment planning [15, 16]. Finally, FDG-PET might be
used during therapy as a predictor to treatment response.
2.InterimPETAsPredictorof Relapse
In two preliminary prospective studies, Hutchings et al.
[17, 18] showed that patients with advanced cHL who were
PET positive after 2 ABVD had a 2-year PFS of 0%–6% by
contrastto94%forthosewithPETnegativeresult.Thosetwo
cohorts were joined and expanded (n = 260) to report the
same results [19]. The prognostic value of the interim PET
completely overshadowed the International Prognostic Score
(IPS).
In a study of 41 patients including 23 cHL, Kostakoglu et
al. performed FDG-PET soon after 1 cycle of chemotherapy
and showed a 2-year progression-free survival for PET-
negative patients after 1 cycle of therapy of 100.0%, com-
pared with only 12.5% (95% CI: 2.1–32.8) in those with
ap o s i t i v er e s u l t[ 20]. The timing of treatment assessment
may be critical, especially to distinguish patients refractory
to ﬁrst-line therapy from those who relapse at a later time.
The former may beneﬁt from very early alternative therapy
avoiding the complications of continued ineﬀective therapy.
Likewise, the identiﬁcation of patients who are likely to be
cured by the ﬁrst-line therapy may oﬀer the potential of
shortening the duration or intensity of treatment.
In a recently published metaanalysis, Terasawa [21]
showed that in 360 advanced cHL, FDG-PET for interim
response assessment had an overall sensitivity of 0.81 (95%
CI: 0.72–0.89) and a speciﬁcity of 0.97 (95% CI: 0.94–0.99).
Because of a 28.4 positive likelihood ratio, positive FDG-PET
results after a few cycles of chemotherapy would probably
have an excellent ability to predict poor responders in
advanced adult cHL. Meta-regression and subgroup analysis
did not identify factors that aﬀect prognosis accuracy.
The positive predictive value (PPV) of FDG-PET in
localised cHL is less ﬁrmly established. In the study of
Hutchings et al. [22], a signiﬁcant proportion of interim
PET-positive patients did not relapse. In order to identify
the group of patients at very high risk for relapse more
accurately, they analysed separately the patients with stage I-
II and stage III-IV. The diﬀerences in PFS between stage I-II
positive and negative was signiﬁcant, but only 2/7 interim
PET-positive patients with early stage have relapsed in
contrast to advanced-stage patients who all relapsed within
2 years in the same circumstances. More recently, Sher et al.
reported that only 3/20 patients with positive interim FDG-
PET relapse in a study population of, mostly stage I-II, cHL
patients. This especially 15% PPV was, however, obtained
in the context of a consolidative radiotherapy given to all
patients (PET positive and negative) [23].
3. Interpretation of Interim PET
3.1. General Considerations. In cHL, the Hodgkin or Reed-
Sternberg cells represents less than 1% of the lymph node
population. They are surrounded by a large number of
mononuclear cells that are very metabolic and responsible
for FDG uptake in vivo. The metabolic viability of such
environment works as an ampliﬁer for the FDG-PET signal,
but might also become negative despite the persistence of a
large tumoral mass.
This anatomopathological aspect is quite diﬀerent from
that observed in non-Hodgkin lymphoma where neoplastic
cells account for 90% of the lymph node population.
Therefore, the timing for interim FDG-PET interpretation
and the guidelines might diﬀer largely between cHL and
NHL, which own diﬀerent biologic behaviour and response
proﬁles.
If the predictive value of FDG-PET depends on the
type of lymphoma, the type of chemotherapy used may
also be of major signiﬁcance. Most of the patients included
in the studies were treated using ABVD. Until recently,
the prognostic value of interim FDG-PET in the context
of BEACOPP regimens in advanced cHL patients was not
established. Avigdor et al. [24] reported a relatively high
negativepredictivevalue(NPV;87%),butamuchlowerPPV
(45%), for interim FDG-PET carried out after two cycles
of BEACOPPesc before decreasing therapy to ABVD. These
ﬁndings were indeed diﬀerent from those observed during
ABVD treatment. Nevertheless, the results of early FDG-PET
still maintained a signiﬁcant long-term prognostic role in
terms of PFS presumably due to the relatively high NPV.
Similarly, Gallamini et al. [25] showed that PET carried
out after two cycles of BEACOPPesc retained its long-term
prognostic role despite a PPV of 60%, which was also much
lower than expected.
3.2. Visual Interpretation and Minimal Residual Uptake
(MRU). In 10% of the patients undergoing early FDG-
PET, a persisting faint residual FDG uptake is recorded,
most often in a site with previous bulky disease. Hutchings
et al. described this new grey-zone as minimal residual
disease (MRU) and deﬁned it as a FDG uptake just above
background, which is unlikely to represent persisting cHLAdvances in Hematology 3
Table 1: Score 3 might be either considered as FDG-PET positive
when a therapy decrease is planned in localised cHL or negative
when treatment intensiﬁcation is planned in advanced cHL.
Five Point scale.
(1) No uptake
(2) Uptake ≤ mediastinum
(3) Uptake > mediastinum but ≤ liver
(4) Uptake moderately more than liver uptake, at any site
(5) Markedly increased uptake at any site and new site of disease.
[22]. MRU probably represents an inﬂammatory reaction
consecutive to chemotherapy with a nonspeciﬁc uptake
of FDG. However, the boundaries of the MRU concept
have evolved during the recent years. Gallamini et al. [19]
considered MRU as a weakly persisting uptake with an
intensity equal or slightly more than the mediastinal blood
pool. In 2008, Barrington et al. proposed a residual uptake
with an intensity lower or equal to the intensity of the liver
[26].ThegoaloftheevolutionofMRUdeﬁnitionistoreduce
the false positive report. The consequence of such evolution
is, however, that diﬀerent MRU deﬁnitions are used among
several trials making comparison extremely hazardous.
3.3. Quantitative Interpretation. Besides visual inspection of
PET images, semiquantitative analyses using standardized
uptake values (SUVs) allow for an objective assessment of
treatment response, thereby eliminating observer variation
and providing the opportunity to reduce the grey-zone by
adding the quantitative power of PET.
However,formulticentrestudies,thecomparisonofSUV
results obtained in diﬀerent centres is still hampered by
the wide variability in the methodology of data acquisi-
tion, image reconstruction, and data analysis procedures.
Therefore, protocols are established for standardisation and
quantiﬁcation of PET [27]. The quantitative assessment
of tumour responses and the comparison among studies
require rigorous quality control, especially if performed
on diﬀerent PET systems or using diﬀerent protocols, and
because of variation among institutions [28].
Current guidelines suggest that a visual assessment of
P E Ts t a t u si sa d e q u a t ea n ds u ﬃcient for a positive or neg-
ative decision after completion of therapy; however, during
treatment or in clinical trials, some form of semiquantitation
may be helpful [29–31]. Cut-oﬀ levels of SUV to determine
response to therapy are also likely to be dependent on
tumour and treatment type, and so, need to be evaluated in
further prospective clinical trials.
3.4. Proposed Guidelines for Interpretation. With the demon-
stration of interim FDG-PET prognostic value in cHL,
diﬀerenttrialshavebeeninitiatedtousesuchinformationfor
individual treatment adaptation. A standardization eﬀort of
FDG-PET interpretation criteria seems particularly relevant
fora potential extension of the method on a worldwide basis.
In 2007, the International Harmonization Project (IHP)
subcommitteedevelopedconsensusrecommendationsinthe
Table 2: Example of cut-oﬀ for therapy (a) decrease in localised
cHL, (b) increase in advanced cHL.
(a)
(1) No uptake
(2) Uptake ≤ mediastinum
(3) Uptake > mediastinum but ≤ liver
(4) Uptake moderately more than liver uptake, at any site
(5) Markedly increased uptake at any site and new site of
disease.
(b)
(1) No uptake
(2) Uptake ≤ mediastinum
(3) Uptake > mediastinum but ≤ liver
(4) Uptake moderately more than liver uptake, at any site
(5) Markedly increased uptake at any site and new site of
disease.
useofFDG-PETinlymphomabasedontheliteratureandthe
collective expertise of its members [29]. Visual assessment
alone was considered adequate for FDG-PET reading after
the completion of therapy. Mediastinal blood pool activity
was recommended as the reference background activity to
deﬁne FDG-PET positivity for a residual mass ≥2cm in
greatest transverse diameter, regardless of its location. A
smaller residual mass or a normal-sized lymph node should
be considered positive if its activity is above that of the
surrounding background. Speciﬁc criteria for deﬁning FDG-
PET positivity in the liver, spleen, lung, and bone marrow
were also proposed. Use of attenuation-corrected PET was
strongly encouraged.
Two drawbacks can be considered for the use of IHP
criteria in interim FDG-PET for cHL. First, these criteria
were developed for interpretation of FDG-PET at the end
of treatment and not speciﬁcally for interim FDG-PET.
Moreover, the aim of PET scan performed at the end of
treatment is diﬀerent from that of interim scan: the ﬁrst
is aimed at assessing the response, the second at assessing
chemosensitivity. For the former the gold standard reference
is the biopsy to demonstrate CR or non-CR, for the second
the gold standard does not exist, at the moment.
Second, these criteria use the lymph node size as cut-oﬀ
for reference background (i.e.: when ≥2cm: background is
the mediastinal blood pool activity, whereas <2c mi ti st h e
surrounding background). As a recent radiological study has
shown the reproducibility of lymph nodes, measurements is
the lowest between 15 to 20mm, a range which might lead
to major discrepancies in FDG-PET interpretation [32]a s
the reference background changes. In 2009, an international
workshop on interim FDG-PET [33]t o o kp l a c ei nD e a u vi l l e ,
France, to reach a consensus on simple and reproducible
criteria for interim FDG-PET. The experts proposed for cHL
that (1) a baseline FDG-PET/CT should be performed prior
to therapy initiation, (2) and that a visual analysis using
a ﬁve point-scale should be applied (Table 1), and (3) for4 Advances in Hematology
Table 3
Name of study Study Group Classiﬁcation PET intervention Phase
20051 (H10) EORTC-GELA-IIL Localized No radiotherapy PET− after 2 ABVD III
RAPID UK NCRI lymphoma group Localized No radiotherapy PET− after 3 ABVD III
HD16 GHSG Localized No radiotherapy PET− after 2 ABVD III
PET adapted chemo GITIL Advanced BEACOPPesc if PET+ after 2 ABVD III
RATHL UK NCRI lymphoma group Advanced BEACOPPesc if PET+ after 2 ABVD II
HD0801 IIL Advanced Salvage if PET+ after 2 ABVD III
HD18 GHSG Advanced BEACOPPesc reduced to 4 cycles if PET2− III
AHL2011 GELA Advanced BEACOPPesc reduced to ABVD if PET2− III
Avigdor et al. [24] Israel Advanced Reduce to 4 ABVD if PET− after 2 BEACOPPesc II
the therapeutic decision, the cut-oﬀ should be determined
according to the strategy (Tables 2(a) and 2(b)). A cohort
of ABVD-treated HL patients was collected with the aim to
validate the proposed criteria. This International validation
study is currently under progress.
Finally, the use of dynamic visual score, which combines
the metabolic evolution of each disease site has been recently
reported to be superior to the binary static scores [34].
3.5. FDG-PET Review System. Despite all these eﬀorts of
reading standardisation, many diﬃculties arise when mini-
mal residual uptake is present. Even with blind assessment,
readers may disagree especially with borderline or complex
cases. Interpretation of FDG-PET is subject to a number
of variables, including the reader experience. Zijlstra et al.
lookedatthescoringof11nuclearmedicinephysicians.They
compared their results with those of an expert interpreter.
The agreement was 82%–94% when the expert reading was
PET-positive, but only 45% when it was PET negative. The
same group also showed that more experienced readers
tended to have fewer false positives, demonstrating the need
for standardization [35].
Especially in the context of clinical trials, it is highly
desirable to establish a reading procedure that synthesizes
the opinions of several experts, potentially from diﬀerent
imaging departments, for reducing the impact of inter
observer variability. A major limitation to this approach
is the necessity to obtain the multiple interpretations in a
clinically relevant time frame (typically less than 72 hours)
in order to modify the therapeutic strategy, if needed, during
the chemotherapy regimen. For these reasons, the classic
retrospective or local blinded independent central review is
not applicable.
The development of such network has been recently
developed by the GELA group [36]. The cornerstone of
the network is a multimodality workstation which allows
side-by-side display of pre- and post-treatment FDG-
PET/computed tomography (CT), as well as complete image
processing, including standardized uptake values analysis. A
central server dispatches the raw data to the workstations of
experts. They make their own independent image processing
and interpretation, and send the optical scan report form
with the result to the central server where an integrated
computation of the interpretations is performed. From June
2007 to November 2008, FDG-PET from 166 consecutive
patientsincludedintheH10studywerereviewed.Sixpercent
discordant PET2 readings were observed between the local
site reader and the central review panel, 73% of them were
modiﬁed from negative to positive. More importantly, a
signiﬁcantly higher inter-observer agreement (P ≤ .0001)
was achieved when the readers could interpret side by side
the PET2 with baseline FDG-PET.
Another network was also established in the United
Kingdom for clinical trial in cHL. This network has been set
up with a “core laboratory” to coordinate quality control and
interpret scans. Images are exchanged via web on a dedicated
website. Recently, a good agreement was reported within this
networkinaseriesof44patientswithstageII–IVcHLtreated
with ABVD (Kappa: 0.85 (95% CI 0.74–0.96)) [37].
4. Ongoing Studies
Diﬀerent trials evaluating FDG-PET response-adapted ther-
apy were recently initiated (Table 3). In localised cHL, all
evaluate omission of radiotherapy for FDG-PET-negative
patients after 2-3 cycles of ABVD. In the EORTC-GELA-
IIL trial, early modiﬁcation of chemotherapy for PET-
positive patients has also been a secondary objective. In
advanced cHL, two diﬀerent strategies have been applied:
either patients who are PET-positive after 2 ABVD will
receive more aggressive chemotherapy or intensiﬁcation
(escaladating strategy) or, in three other trials, patients who
are PET-negative after 2 BEACOPPesc receive less cycles of
r e g i m e no rs w i t c ht oA B V D( r e d u c i n gs t r a t e g y ) .
5. Conclusions
Prognostic accuracy studies of interim FDG-PET for
advanced-stage HL have consistently reported excellent
speciﬁcity and moderately good sensitivity.
The reported prognostic accuracy is reasonably applica-
ble to low- or intermediate-risk advanced-stage HL patients
undergoingABVDﬁrst-linetherapy.Itisunclearwhetherthe
accuracy can also be applied to high-risk patients in whom
BEACOPPescisused.Moreover,theinterpretationofinterim
FDG-PET is still the subject of debate and controversies, so
that no consensus is currently reached.Advances in Hematology 5
Thus, the additional prognostic value of interim FDG-
PET in the current management strategies is still unclear and
its use should still be reserved for research settings.
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